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LETTER TO THE EDITOR
Response to the letter from Drs Gold and Osband
Sir - We believe, like Drs Gold and Osband, that application
of CD45RO+CD4+ helper/killer cells to adoptive immuno-
therapy has many advantages for the potentiation of host
antitumour immunity. In previous papers (Nishimura et al.,
1991; 1992a,b; Nakamura et al., 1992) we initially developed
a large-scale culture system of pure human CR45RO+CD4+
T cells. We intend to use these CD4+ T cells for new trials of
adoptive immunotherapy, termed 'helper/killer therapy', in
combination with other kinds of killer cells (CD8+T or 76T)
and bispecific antibody (BSAb). Recent results have demon-
strated that introduction of local help by gene technology
resulted in the rejection of tumour cells of low immuno-
genicity (Fearon et al., 1990). Therefore, we believe that the
targeting of both CD4+ helper T cells and CD8+ T cells
using BSAb may facilitate the activation of antitumour
immunity at the local site of a tumour.
In the letter from Drs Gold and Osband, they claim that
their developed autolymphocyte therapy (ALT) is adoptive
tumour immunotherapy based upon the infusion of CD4+
CD45RO+ T cells activated with OKT3 and OKT3-stimu-
lated conditioned medium (T3CS). However, we cannot find
any evidence that they used CD4+CD45RO+ enriched T cell
populations for ALT. As described in their own paper
(Osband et al., 1990), the cells used for ALT consisted of
49.6% T cells and 51.4% other non-T cell populations. T
cells consisted of 45.6% CD4+ T cells and 18.4% CD8+ T
cells. Furthermore, activation of peripheral blood lym-
phocytes, which contained 26.7% CD4+CD45RO+2H4- T
cells, with OKT3 mAb and T3CS did not cause preferential
growth of the CD4+CD45RO+ (2H4-) T cell population
(24.2%). As described in their basic study (Celis et al., 1991)
and other results (Panzer et al., 1990), it was demonstrated
that the activation ofpurified CD4+ T cells with IL-1 or IL-1
containing T3CS resulted in the preferential growth of CD4+
CD45RO+ T cells. Therefore, the activation of isolated
CD4+ T cells with OKT3 mAb plus T3CS may improve the
yield of CD4+CD45RO+ T cells and may therefore confer
benefits for the therapeutic effect of ALT. In summary, our
answer to their first question is that we can agree the work-
ing hypothesis of ALT using CD4+CD45RO+ T cells, but we
cannot find any evidence from their data that unseparated
PBL are sufficient to induce preferential growth of CD4+
CD45RO+ T cells useful for adoptive tumour immuno-
therapy.
It is very interesting results that a certain threshold dose of
infused lymphocytes was critical for the therapeutic effect of
adoptive immunotherapy (Ross & Osband, 1989). They claim
that the suppressive effect of a large number of cells
(12-15 x 106 cells/KG/infusion) might be derived from the
CD4+CD45RO+ T cells which may cause an 'anti-idiotypic'
reaction with concomitant generation of suppressor cells.
This might be true if they use pure CD4+CD45RO+ T cells
for ALT. As described above, however, they used hetero-
geneous cell population which contained only 24.6% CD4+
CD45RO+ T cells. Therefore, it is not necessary to speculate
that infusion of a large number of CD4+ T cells might
suppress antitumour activity. They cannot exclude the pos-
sibility that classical CD8+ suppressor T cells showed in vivo
suppressive activity. Nevertheless, their results provide
important information concerning the number of cells used
for adoptive immunotherapy. The aims of ALT and helper/
killer therapy seem to be different. The aim of the former is a
potentiation of host antitumour immunity by systemic adop-
tive transfer. The aim of the latter is the targeting ofCD4+ T
cells and CD8+ T cells into the tumour tissues via the
tumour-feeding artery in combination with BSAb. In the case
of systemic administration, a small number of CD4+ T cells
might be sufficient for immunoregulatory action in vivo. In
contrast, large numbers of CD4+ T cells with CD8+ killer T
cells may be necessary for BSAb-dependent induction of IL-2
production and tumour eradication at the local sites because
tumour cells produce immunosuppressive factors.
In conclusion, we believe that separation of CD4+ T cells
from PBL before culture is essential for selective growth of
CD4+CD45RO+ T cells and that a large number of CD4+ T
cells may be necessary for the augmentation of local effects at
local sites of tumour involvement. We hope that Drs Gold
and Osband will demonstrate improved therapeutic effects of
ALT using controlled pure CD4+ and CD8+ T cell popula-
tions.
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